Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
Mefatinib demonstrated superior efficacy to gefitinib with a similar tolerability profile in the first-line treatment of EGFR-mutated advanced NSCLC with common and uncommon EGFR-activating mutations.
Jia Yu, Anwen Xiong, Qi-Ming Wang et al.· Signal Transduction and Targ...· 0 citations
Osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations, and provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC.
Ting Zhou, Huaqiang Zhou, Fangfang Gao et al.· Journal of the American Medi...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.